Innovent Biologics
2000 Alameda de las Pulgas, suite 120
San Mateo
CA
94403
United States
Website: http://www.innoventbio.com/
81 articles with Innovent Biologics
-
Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Dual Glucagon-like Peptide-1 and Glucagon Receptor Agonist in Chinese Patients with Type 2 Diabetes at the International Diabetes Federation Congress 2021
12/6/2021
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that results of a phase 1 clinical trial of IBI362 (LY3305677).
-
Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications
12/3/2021
Innovent Biologics, Inc. and Eli Lilly and Company, announce that the innovative PD-1 inhibitor sintilimab has been successfully included in the updated National Reimbursement Drug List for all approved indications, according to the latest announcement from the China National Healthcare Security Administration.
-
Innovent Biologics and Ascentage Pharma Announce the China NMPA Approval for China's First Third-Generation BCR-ABL Inhibitor Olverembatinib for the Treatment of Chronic Myeloid Leukemia
11/30/2021
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), and Ascentage Pharma (6855.HK), today announce that the novel drug olverembatinib has been approved by the China National Medical Products Administration (NMPA).
-
Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib, Marking a Clinical Breakthrough in the Treatment of Chronic Myeloid Leukemia
11/30/2021
Ascentage Pharma (6855.HK), and Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), jointly announce that the novel drug candidate olverembatinib of Guangzhou HealthQuest Pharma Co., Ltd., Inc., a wholly-owned subsidiary of Ascentage Pharma, has been approved by the China National Medical Products Administration (NMPA).
-
Innovent Announces Inclusion of the Company's Stock (01801.HK) in the Hang Seng China Enterprises Index
11/22/2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces the Company's stock is included in the Hang Seng China Enterprises Index according to the Hang Seng Indexes Company's latest results of review.
-
Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology
11/15/2021
Innovent Biologics, Inc. announces that the results of the Phase Ib clinical trial of IBI302, a first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bi-specific fusion protein for neovascular age-related macular degeneration is released in e-poster at 2021 American Academy of Ophthalmology.
-
Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1/CD137 Bispecific Antibody) in Nature Communications
11/8/2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the preclinical result of IBI319 was published in Nature Communications.
-
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Treatment for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
11/4/2021
Innovent Biologics, Inc. announced that the National Medical Products Administration of China has accepted the supplemental New Drug Application for sintilimab in combination with chemotherapy for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.
-
Innovent and NeoCura Announce Strategic Collaboration to Study the Combination Therapy of Sintilimab and Neoantigen Vaccine NEO_PLIN2101 for Cancer Treatment in China
10/28/2021
Innovent Biologics, Inc. and NeoCura Bio-Medical Technology Co., Ltd. jointly announced that they have entered into a strategic collaboration agreement to carry out a clinical study in China on the combination therapy of sintilimab from Innovent and individualized neoantigen vaccine NEO_PLIN2101 from NeoCura.
-
Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer with Prior EGFR-TKI Treatment, Has Met Primary Endpoint
10/18/2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announced that the sintilimab ORIENT-31 study has met its prespecified primary endpoint of progression-free survival at the first interim analysis.
-
It was a busy week for clinical trial news. Here’s a look.
-
Innovent Releases Preliminary Results of the Phase Ia Dose-Escalation study of IBI315 (Anti-Her2/PD-1 Bispecific Antibody) in Patients with Advanced Solid Tumors at CSCO Annual Meeting 2021
9/29/2021
Innovent Biologics, Inc.released the preliminary results of the Phase Ia study of IBI315 (first-in-class anti-Her2/PD-1 bispecific antibody) in an oral presentation at the 2021 Annual Meeting of Chinese Society of Clinical Oncology (CSCO).
-
Innovent Announces the First Patient Dosed in the Phase I/II Study of IBI351 (KRAS G12C inhibitor) in Patients with Advanced Malignant Tumors
9/29/2021
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), today announced a phase I/II clinical study of KRAS G12C inhibitor IBI351 in Chinese patients with solid tumors (ClinicalTrials.gov, NCT05005234) completed dosing of the first subject.
-
UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions
9/28/2021
UNION therapeutics A/S and Innovent Biologics Limited announced that they have entered into a strategic collaboration and license agreement for the development and commercialization of orismilast in China.
-
Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions
9/28/2021
Innovent Biologics, Inc. and UNION therapeutics A/S today announced that they have entered into a strategic collaboration and license agreement for the development and commercialization of orismilast in China.
-
AnHeart and Innovent Announce Interim Data from Phase Ⅱ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
9/27/2021
AnHeart Therapeutics Co., Ltd together with Innovent Biologics, Inc. announced today interim clinical data from a Phase Ⅱ trial (TRUST) evaluating taletrectinib (AB-106)
-
Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
9/27/2021
Innovent Biologics, Inc. and AnHeart Therapeutics Co., Ltd jointly announced the interim clinical data from a Phase 2 trial evaluating taletrectinib, an investigational next-generation ROS1/NTRK inhibitor in ROS1-positive non-small cell lung cancer.
-
Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis
9/23/2021
Innovent Biologics, Group. ("Innovent") (HKEX: 01801), today announced that the first patient with moderate-to-severe plaque psoriasis has been successfully dosed in a Phase 2 clinical trial (clinicaltrials.gov, NCT05003531) of recombinant anti-interleukin 23p19 subunit antibody injection (R & D code: IBI112) in China.
-
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Therapy for Esophageal Squamous Cell Carcinoma (ESCC)
9/22/2021
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), today announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for Sintilimab in combination with chemotherapy (cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil) for the first-line treatment of esophageal squamous cell carcinoma (ESCC).
-
Innovent Releases Interim Analysis Results of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma in the Phase 3 ORIENT-15 Study at ESMO Congress 2021
9/18/2021
Innovent Biologics, Inc. announced that the interim analysis results of the Phase 3 ORIENT-15 study evaluating sintilimab in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma were released in an oral presentation at the European Society for Medical Oncology Congress 2021.